PMV Pharmaceuticals announces promising updated data from the PYNNACLE Phase 2 pivotal trial of Rezatapopt monotherapy in patients with advanced solid tumors harboring the TP53 Y220C mutation.
PMV Pharmaceuticals announces promising updated data from the PYNNACLE Phase 2 pivotal trial of Rezatapopt monotherapy in patients with advanced solid tumors harboring the TP53 Y220C mutation.
Want to see every report in real time?
Hundreds of sources worldwide, translated into your language, with alerts for what matters to you.
Sign up free Already have an account? Log in